BMS Immunotherapy Strategic Update at JP Morgan Conference

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
Posts: 510
Joined: Tue Sep 17, 2013 8:31 am
Location: San Diego

BMS Immunotherapy Strategic Update at JP Morgan Conference

Postby DK37 » Wed Jan 13, 2016 1:43 am

From BMS's presentation at the big JP Morgan Healthcare conference going on right now, the major immunooncology drug company (Opdivo, Yervoy) mentioned prominently an interest in addressing "tougher tumors" like CRC and pancreatic.....

They then go into their very long second generation 2015-2016 trial start pipeline of which e.g. I am keep close eye on e.g. how the anti-CSF1R and anti-CD73 trials do (among others trials as well) as multiple attempts are being made to remove immunosupression from "cold" tumors like MSS-CRC. ... ipt?page=3

Quotes from their presentation this week:
"Beyond the combination of Yervoy and Opdivo, we are investigating novel mechanisms of action to be used in combination with Opdivo as a backbone agent. Our objective is to address the need of patients that do not respond to Opdivo, to patients that relapse after a response to Opdivo and obviously to seek signals in those tumors where the current signals are not strong,such as for example pancreatic and BROADLY COLORECTAL CANCER (emphasis added).

Beyond the focus on Opdivo and Yervoy, we are developing a really attractive pipeline of new agents, which are in early stage of development. I won’t go into a lot of detail on this slide but I’m actually very excited to have five agents in the clinic; anti-LAG3, Urelumab, anti-GITR, Lirilumab and the anti-CSF1R and to be adding three more agents in the clinic in 2016, the IDO, anti-CD73 and anti-OX40. So in 2016 we will have eight novel agents in the clinic and look forward to advancing every one of those programs."

6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder:
2016 Colondar 2.0 Model
DK37 Science Posts List

Posts: 649
Joined: Sun Sep 13, 2015 6:16 pm

Re: BMS Immunotherapy Strategic Update at JP Morgan Conference

Postby mariane » Wed Jan 13, 2016 8:53 am

Fingers crossed!
mom of now 9 years old twins, dx @ 40 in 6/2015 with upper rectal cancer, 10+ liver mets, CEA 140
chemo: 8/2015 - 10/2016 - 4xFOLFIRINOX, 2xFOLFOX, 8xFOLFIRI, 10x5FU, HAI pump -12xFUDR
4 surgeries, complete pathological response
CEA<2 since 10/2015
NED since May 2016

I praise God for every day with my family!

Posts: 21
Joined: Wed Aug 26, 2015 7:55 am

Re: BMS Immunotherapy Strategic Update at JP Morgan Conference

Postby JFrog » Wed Jan 13, 2016 10:05 am

You got to believe with this many "shots on goal" with good preclinical modeling that at least one of these will help the MSS mCRC community.
DW dx 5/2012 Stage II @ age 45; MSS;
Emergency colostomy
5FU radiation
Resection 10/2012 and FOLFOX
Recurrence local and liver 5/2013
FOLFIRI 8 rds, Xeloda and repeat radiation
Liver res. 3/2014, repeat pelvic res. 7/2014
Liver(2) and lung recurrence(1) 9/2014, Iri w/ pan until progression then FOLFOX w/ Avastin until progression
MDA Targeted Therapy Clinical Trial 8/2015, Progressed10/15-off trial
Iri and pan. 11/2015
SBO 2/16 with successful resection 3/9/16
Clinical Trial AZD1775, 4/21/16

Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”

Who is online

Users browsing this forum: Beckster, Majestic-12 [Bot], Purplecat and 32 guests